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Autologous hematopoietic stem cell transplantation (AHCT) improves survival inpatientswithmultiplemyeloma
(MM) but is associated with morbidity and nonrelapse mortality (NRM). Hematopoietic cell transplant comor-
bidity index (HCT-CI) was shown to predict risk of NRM and survival after allogeneic transplantation. We tested
the utility of HCT-CI as a predictor of NRM and survival in patients with MM undergoing AHCT. We analyzed
outcomes of 1156 patients of AHCT after high-dose melphalan reported to the Center for International Blood and
Marrow Transplant Research. Individual comorbidities were prospectively collected at the time of AHCT. The
impact of HCT-CI and other potential prognostic factors, including Karnofsky performance score (KPS), on NRM
and survival were studied in multivariate Cox regression models. HCT-CI score was 0, 1, 2, 3, and >3 in 42%, 18%,
13%, 13%, and 14% of the study cohort, respectively. Subjects were stratiﬁed into 3 risk groups: HCT-CI score of
0 (42%) versusHCT-CI score of 1 to2 (32%) versusHCT-CI score> 2 (26%).HigherHCT-CIwas associatedwith lower
KPS < 90 (33% of subjects score of 0 versus 50% in HCT-CI score > 2). HCT-CI score > 2 was associated with
melphalan dose reduction (22% versus 10% in score 0 cohort). One-year NRM was low at 2% (95% conﬁdence
interval, 1% to 4%) and did not correlate with HCT-CI score (P ¼ .9). On multivariate analysis, overall survival was
inferior in groupswithHCT-CI score of 1 to 2 (relative risk,1.37, [95% conﬁdence interval,1.01 to 1.87], P¼ .04) and
HCT-CI score> 2 (relative risk,1.5 [95% conﬁdence interval,1.09 to 2.08], P¼ .01). Overall survivalwas also inferior
with KPS< 90 (P < .001), IgA subtype (P  .001), those receiving>1 pretransplant induction regimen (P ¼ .007),
and those with resistant disease at the time of AHCT (P < .001). AHCT for MM is associated with low NRM, and
death is predominantly related to disease progression. Although a higherHCT-CI score didnot predictNRM, itwas
associated with inferior survival.
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13.12.557INTRODUCTION
High-dose melphalan (MEL) followed by autologous he-
matopoietic stem cell transplantation (AHCT) is widely used
to treat patients with multiple myeloma (MM) [1,2]. Risk
stratiﬁcation and selection of patients before AHCT dependsTransplantation.
Figure 1. Distribution of HCT-CI among the patient cohort (N ¼ 1156).
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tainty regarding how well older patients tolerate high-dose
therapy has resulted in arbitrary age limits for performing
AHCT [3]. The discrepancy between chronological and
physiological age is likely inﬂuenced by comorbidities.
Consequently, comorbidity indices have been developed to
assess the tolerability of the allogeneic and autologous
transplants.
The Charlson Comorbidity Index (CCI) has previously
been used to predict mortality in cancer patients [4]. How-
ever, the CCI included some rarely encountered comorbid-
ities (such as dementia, AIDS, and metastatic cancer) among
transplant patients and lacks precise grading (such as mild,
moderate, and severe) of some comorbidities (renal, hepatic,
and pulmonary functions). The hematopoietic cell transplant
comorbidity index (HCT-CI) scoring system, subsequently
developed by Sorror et al., has been shown to be a better
predictor of nonrelapse mortality (NRM) after allogeneic
transplantation in patients with hematological malignancies,
including MM [5-9]. The HCT-CI is a weighted index of 15
pretransplant comorbidities that includes laboratory evalu-
ation of some comorbidities. Patients may have a minimum
score of 0 and a maximum score of 26 (Supplementary
Table 1), noting mutually exclusive scores (mild/moderate
hepatic and moderate/severe pulmonary comorbidity score)
[8,10].
MM is associated with a variety of end-organ compro-
mise, such as renal dysfunction, bone disease, neuropathy,
and anemia and repeated infections [11]. It is possible that
the tolerance of myeloma patients to high-dose therapy with
AHCT is different from patients with other hematological
neoplasms. Identifying a comorbidity scoring system for
tolerability of AHCT in patients with MM helps the selection
of patients for such intensive therapy. In this study, we used
the database of the Center for International Blood and
Marrow Transplant Research (CIBMTR) to study the impact of
the pretransplant HCT-CI on the clinical outcome after AHCT
of MM patients, speciﬁcally NRM and overall survival (OS).METHODS
Data Source
The CIBMTR is a research afﬁliation of the International Bone Marrow
Transplant Registry, the Autologous Blood and Marrow Transplant Registry,
and the National Marrow Donor Program. It comprises a voluntary group of
more than 450 transplant centers worldwide that contribute their detailed
data on consecutive allogeneic and autologous transplants to a statistical
center at the Health Policy Institute of the Medical College of Wisconsin in
Milwaukee or the National Marrow Donor Program Coordinating Center in
Minneapolis, Minnesota. Participating centers are required to register all
transplants done consecutively. Compliance of the participating centers is
monitored by periodic on-site audits. Patients are followed up longitudi-
nally, with yearly data update. Computerized checks for errors, physicians’review of submitted data, and on-site audits of participating centers alto-
gether ensure data quality. Observational studies conducted by the CIBMTR
are performed with a waiver of informed consent and in compliance with
Health Insurance Portability and Accountability Act regulations as deter-
mined by the institutional review board and the privacy ofﬁcer of the
Medical College of Wisconsin. All CIBMTR centers contribute to the regis-
tration data. Research data are collected on a subset of registered patients
and include detailed disease and pretransplant and post-transplant clinical
information.Patients
A total of 1156 patients who underwent AHCT (including tandem and
second salvage transplant) between 2007 and 2010 were identiﬁed who had
received high-dose MEL alone as a conditioning regimen and had available
complete information of comorbidity scores. All patients whowere alive had
at least a 100-day follow-up.Assessment of Comorbidities
Information of the comorbidities was obtained from prospectively re-
ported records in the CIBMTR database. All patients were assigned an HCT-CI
score based on the criteria reported by Sorror et al. [8] (Supplementary
Table 1). A total of 489 patients had an HCT-CI score of 0 (366 patients
had no comorbidity and 123 patients had comorbidities not included in the
HCT-CI schema). The remaining 667 patients had at least 1 of the HCT-CI
comorbidities and received a score ranging from 1 to 11. Distribution of
HCT-CI scores of the study cohort is shown in Figure 1.Statistical Method
Descriptive statistics were used to summarize the characteristics of the
study population. Median value and range were used for continuous vari-
ables. Frequency and percentage were used for categorical variables. Group
comparisons were done by the Kruskal-Wallis test, chi-square test, and
Fisher exact test. Survival probabilities were calculated by using the Kaplan-
Meier estimator with the variance estimated by Greenwood’s formula.
NRM was deﬁned as mortality after transplant in the absence of disease
relapse or progression. Thus, the cumulative incidence probabilities for NRM
were calculated accounting for relapse as a competing risk. Point-wise
comparison and log rank analysis were used to analyze the NRM and sur-
vival of different groups. Multivariate analysis was performed using Cox
proportional hazard regression model. Variables analyzed included HCT-CI,
age, gender, myeloma subtype and stage, MEL dose, number of chemo-
therapy regimens before transplant, disease sensitivity before transplant,
Karnofsky performance score (KPS), and time from diagnosis to transplant
(Supplementary Table 2). Forward stepwise variable selection at a .05 sig-
niﬁcance level was used to identify covariates. In the model, the assumption
of proportional hazards was tested for each variable using a time-dependent
covariate and graphical methods.
All variables considered in the multivariate analysis satisﬁed the pro-
portionality assumption. All computations were made using the statistical
package SAS version 9.1 (SAS Institute, Cary, NC).RESULTS
Patient Characteristics
Subjects were classiﬁed into 3 groups based on HCT-CI
scores: low risk (HCT-CI ¼ 0), intermediate risk (HCT-CI ¼ 1
to 2), and high risk (HCT-CI > 2). Characteristics of the pa-
tients in the 3 groups are shown in Table 1. The distribution
Table 1
Patient Characteristics of the 3 Groups (HCT-CI Score ¼ 0, 1 to 2, and 3)
Characteristic HCT-CI ¼ 0
n (%)
HCT-CI ¼ 1-2
n (%)
HCT-CI > 2
n (%)
P
Patients 489 365 302
Centers 75 68 58
Age at transplant, y, median (range) 58 (18-80) 59 (22-75) 60 (34-79)
18-39 20 (4) 10 (3) 6 (2) .12
40-49 70 (14) 53 (15) 32 (11)
50-59 199 (41) 141 (39) 112 (37)
60-65 93 (19) 88 (24) 70 (23)
65-70 78 (16) 57 (16) 55 (18)
70-80 29 (6) 16 (4) 27 (9)
Gender
Female ¼ 468 (40%) 224 (46) 131 (36) 113 (37) .006*
Race
White ¼ 919 (79%) 410 (84) 277 (76) 232 (77) .02*
Black ¼ 210 (18%) 72 (15) 75 (21) 63 (21)
Othery ¼ 27 (2%) 7 (1) 13 (4) 7 (2)
KPS
90% 302 (62) 203 (56) 126 (42) <.001*
<90% 163 (33) 149 (41) 152 (50)
Missing 24 (5) 13 (4) 24 (8)
Subtype of MM
IgG 294 (60) 206 (56) 168 (56) .34
IgA 108 (22) 73 (20) 66 (22)
Light chain 76 (15) 69 (19) 57 (19)
Otherz 2 (<1) 5 (1) 4 (1)
Nonsecretory 9 (2) 12 (3) 7 (2)
International stage at diagnosis
Stage I 142 (29) 95 (26) 73 (24) .15
Stage II 111 (23) 84 (23) 64 (21)
Stage III 67 (14) 68 (19) 65 (22)
Missing 169 (35) 118 (32) 100 (33)
Transplant-related characteristics
Melphalan dose
140 mg/m2 48 (10) 47 (13) 65 (22) <.001*
160 mg/m2 73 (15) 52 (14) 19 (6)
200 mg/m2 368 (75) 266 (73) 218 (72)
Lines of chemotherapy before transplant
1 231 (47) 140 (38) 128 (42) .06
2 157 (32) 122 (33) 98 (32)
>2 101 (21) 103 (28) 76 (25)
Time from diagnosis to transplant, mo
<12 357 (73) 241 (66) 201 (67) .05
>12 132 (27) 124 (34) 101 (33)
Number of transplants
1 transplant 396 (81) 316 (87) 265 (88) .06
2 transplants, 2nd tandem transplant 51 (10) 28 (8) 17 (6)
2 transplants, 2nd salvage transplant 42 (9) 21 (6) 20 (7)
Very good partial response 107 (22) 83 (23) 63 (21)
Partial response 245 (50) 173 (47) 164 (54)
Stable disease 24 (5) 23 (6) 26 (9)
Progression/relapse 31 (6) 26 (7) 17 (6)
Sensitivity of chemotherapy before transplant
Sensitive 434 (89) 316 (87) 259 (86) .42
Resistant 55 (11) 49 (13) 43 (14)
* Statistically signiﬁcant difference.
y Other includes Asian, Alaskan, Middle Eastern, Hawaiian, and Indian (Native American).
z Other immunochemical subtypes are IgD, IgE, and IgM.
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shown in Supplementary Table 3.
The HCT-CI scorewas 0,1, 2, 3, and>3 in 42%,18%,13%,13%
and 14%of the study subjects, respectively. Themost common
comorbidities were pulmonary, diabetes, obesity, psychiatric,
cardiac, renal, and history of prior solid neoplasm.
Males (P¼ .006), African Americans (P¼ .02), and patients
with lower KPS (P < .001) had signiﬁcantly higher HCT-CI
scores. Patients with higher HCT-CI scores were more likely
to receive a lower MEL dose (140 mg/m2; 22% with HCT-CI
score > 2 versus 10% with HCT-CI score ¼ 0, P < .001).
More patients with higher HCT-CI scores were transplanted
in recent years (P < .001). Other patient-, disease-, ortransplant-related factors did not differ signiﬁcantly be-
tween the 3 groups.
Survival Analysis
The 3-year OS was 76% (95% conﬁdence interval, 70% to
80%) for the HCT-CI score of 0 group and 71% (95% conﬁdence
interval, 77% to 84%) for the HCT-CI score > 0 group (P ¼ .02)
(Figure 2). Therewas no difference in OS among patients who
received MEL doses of 140 and 200 mg/m2 (data not shown).
Patients with higher HCT-CI scores were more likely to
receive MEL 140 mg/m2; however, there was no difference in
OS in this subset of patient (with an HCT-CI score > 0)
receiving lower MEL doses (P ¼ .68) (Figure 3).
Figure 2. OS of the 3 risk groups (HCT-CI score ¼ 0, 1-2, and 3). RR indicates relative risk.
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The cumulative incidence of transplant-related mortality
at 1 year was 2% (95% conﬁdence interval, 1% to 4%) for the
HCT-CI score of 0 group. For HCT-CI score > 2, transplant-
related mortality at 1 year was 2% (95% conﬁdence interval,
1% to 4%), respectively. The main cause of death in the cohort
was disease relapse and progression (Table 2).Multivariate Analyses
OS was worse in the groups with HCT-CI scores of 1 to 2
(relative risk [RR], 1.37 [95% conﬁdence interval, 1.01 to 1.87],
P ¼ .04) and HCT-CI scores > 2 (RR, 1.5 [95% conﬁdence in-
terval, 1.09 to 2.08], P ¼ .01) when compared with groups
with HCT-CI scores of 0. There was no difference in OS be-
tween the groups with HCT-CI scores > 2 and HCT-CI scores
of 1 to 2 (RR, 1.09 [95% conﬁdence interval, 1.79 to 1.52], P ¼
.6). Because there was no difference in survival between the
groups with HCT-CI scores of 1 to 2 and scores > 2, these
groups were combined in subsequent analyses designated as
HCT-CI scores > 0 (n ¼ 667) and were compared with the
group with HCT-CI scores of 0 (n ¼ 489). Variables includedFigure 3. OS in patients with an HCT-CI score > 0in the multivariate analysis are listed in Supplementary
Table 2, and results are summarized in Table 3.
Signiﬁcant predictors of worse OS were HCT-CI score >
0 (RR, 1.33 [95% conﬁdence interval, 1.01 to 1.75], P ¼ .04)
(Figure 4), IgA myeloma (RR, 1.64 [95% conﬁdence interval,
1.21 to 2.21], P ¼ .001), >1 chemotherapy regimen before
transplant (RR, 1.47; P ¼ .007), refractory MM at transplant
(RR,1.78; P< .001), and KPS< 90 (RR, 1.6; P< .001). The HCT-
CI (0 versus >0) did not inﬂuence OS in patients age > 65
years at the time of transplant (P ¼ 0.16). Age did not show a
statistically signiﬁcant inﬂuence on OS or NRM. NRM was
higher in patients who received transplant> 12months after
initial diagnosis (RR, 2.09 [95% conﬁdence interval, 1.16 to
3.75], P ¼ .01). HCT-CI did not predict NRM.DISCUSSION
We sought to evaluate the impact of medical comorbid-
ities on the outcome of MM patients undergoing AHCT using
the HCT-CI, an instrument validated predominantly in the
allogeneic transplant population. Although higher HCT-CI
scores did not affect NRM, they were associated withreceiving MEL doses of 140 and 200 mg/m2.
Table 2
Cause of Death after Transplant in 2 Subgroups with HCT-CI Scores of 0 and
>0
HCT-CI Score ¼ 0 HCT-CI Score > 0
Number of patients 489 667
Number of deaths 84 143
Primary disease 62 (74) 118 (83)
Infection 9 (11) 8 (6)
Organ failure 2 (2) 5 (3)
Vascular 2 (2) 1 (<1)
Secondary malignancy 1 (1) 1 (<1)
ARDS 1 (1) 2 (1)
Hemorrhage 1 (1) 0 (0)
Idiopathic pneumonia 0 (0) 1 (<1)
Unknown 6 (7) 7 (5)
Values in parentheses are percents. ARDS indicates acute respiratory
distress syndrome.
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mortality after AHCT for MM limits our ability to detect the
effect of higher HCT-CI scores on this outcome.
Interestingly, the HCT-CI remains a robust factor predic-
tive of lower OS after AHCT. This association is likely multi-
factorial. Because NRM was not increased among subgroups
with higher scores, these patients eventually succumbed to
MM progression. It may be hypothesized that aggressive
disease resulted in more comorbidities (such as renal or
cardiac dysfunction or infections) that contributed to higher
HCT-CI scores and also resulted in inferior OS. Our data show
the prevalent practice of MEL dose reduction (<200 mg/m2)
in patients with higher HCT-CI scores. However, themere use
of lower doses of MEL was not correlated to inferior survival
by multivariate analysis, and this practice perhaps permitted
a larger number of patients to proceed to AHCT.
Other factors that also independently contributed to
inferior OS in our study were the use of more than 1 line of
chemotherapy regimen before transplant, refractory disease
at the time of transplant, and KPS < 90. The ﬁnding that aTable 3
Multivariate Analysis for NRM and OS of Groups with HCT-CI Scores of
0 vs. >0
NRM Hazard Ratio P
Main effect (HCT-CI score)
HCT-CI > 0 vs. HCT-CI ¼ 0 1.04 (0.58-1.87) .9
Time from diagnosis to transplant
>12 vs. <12 mo 2.09 (1.16-3.75) .01
Age at transplant, y
50-60 vs. <50 1.36 (0.49-3.74) .6
>60 vs. <50 1.88 (0.72-4.95) .2
OS Hazard Ratio P
Main effect (HCT-CI score)
HCT-CI > 0 vs. HCT-CI ¼ 0 1.33 (1.01-1.75) .04
Isotype
IgA vs. IgG 1.64 (1.21-2.21) .001
Light chain vs. IgG 0.77 (0.52-1.15) .2
Others vs. IgG 1.19 (0.60-2.36) .6
Lines of chemotherapy
>1 vs. 1 1.47 (1.11-1.94) .007
Sensitive to chemotherapy
Resistant vs. sensitive 1.78 (1.29-2.46) .0005
KPS
< 90 vs. 90 1.61 (1.22-2.11) .0007
Missing vs. 90 1.50 (0.85-2.63) .2
Age at transplant, y
50-60 vs. <50 0.98 (0.66-1.47) .9
>60 vs. <50 1.22 (0.82-1.80) .3
Values in parentheses are the 95% conﬁdence interval of the hazard ratio.lower KPS is a stronger predictor of inferior OS is similar to
previously reported data in allogeneic transplant patients
[12]. Although IgA myeloma is traditionally associated with
worse outcome, it has not been shown previously to inﬂu-
ence survival after AHCT [13,14]. Our ﬁnding of inferior OS in
patients with IgA disease warrants further investigations
because these patients may derive more beneﬁt from
maintenance therapy after transplant.
In our cohort, NRM was higher in patients who received
AHCT > 12 month after initial diagnosis (RR, 2.09 [95% con-
ﬁdence interval, 1.16 to 3.75], P ¼ .01). This may be attributed
to delaying transplant in physically unﬁt patients until
improvement of KPS or controlling comorbid illnesses or
disease complications. Our study cohort also included pa-
tients who had double (either tandem or salvage) AHCT (19%
of patients with an HCT-CI score ¼ 0 and 13% with an HCT-CI
score > 0). The use of double transplantation was similar
among patients who received transplant > 12 months and
<12 months from diagnosis (12% and 17%, respectively).
Thus, more intense AHCT therapy per se cannot explain the
NRM difference between these 2 groups.
Previous smaller studies have evaluated the inﬂuence of
comorbidities on outcomes of AHCT inMM and lymphoma. A
series of 126 patients who underwent AHCT for MM found
that any comorbidity scored in the CCI or HCT-CI to be
associated with increased transplant morbidities (organ
toxicity) and prolonged hospital stay [15]. Similar ﬁndings
were also seen in patients with lymphoma [16,17]. For
example, a retrospective analysis of lymphoma patients un-
dergoing AHCT showed that a higher CCI score (and not age)
was correlated with higher NRM and lower OS [17].
Our data from a large, multicenter cohort of patients
treated with MEL only as the conditioning regimen suggest
that AHCT for MM is safe even in those with higher HCT-CI
scores. The use of the HCT-CI that was initially validated in
the setting of allogeneic transplant may be a weakness
because it may not be the optimal index for evaluating MM
patients undergoing AHCT. Our ﬁndings have important
implications for the clinical practice of AHCT in MM. First, it
does not appear that use of the HCT-CI offers an advantage
over performance status assessment in predicting risk of
NRM in MM patients undergoing AHCT. Second, age and
comorbidities did not seem to impact NRM, which supports
the safety and continued use of MEL-based transplant in
these populations. Third, KPS and the HCT-CI are both useful
predictors of OS. These data are consistent with an Interna-
tional Myeloma Working Group analysis that suggested age
(younger versus older than 50 years) was not an independent
predictor of survival for patients with MM receiving AHCT
[18]. Most study patients were white (79%), with the black
population represented by 18% and other minorities by only
2%. Because some comorbidities may be more prevalent
among certain ethnicities, these data are to be interpreted
with caution in these ethnic groups.
Limitations inherent to our registry analyses include its
retrospective nature and heterogeneity among practitioners
in selecting MM patients for transplant. Thus, selection bias
in some centers may have precluded patients with certain
comorbidities from having transplants.
In conclusion, a higher HCT-CI score did not predict NRM
butwas associatedwith inferior survival in patients withMM
undergoing AHCT. KPS remains an important predictor of
survival. Future studies are need to develop comorbidity
indices (that may include functional assessment such as KPS)
that are more predictive of NRM after AHCT in MM patients.
Figure 4. OS of patients with different HCT-CI scores with (A) MEL doses of 140 mg/m2 and (B) MEL doses of 200 mg/m2.
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Supplementary Table 1
Criteria for Calculation of HCT-CI Scores
Comorbidities Deﬁnitions HCT-CI Score
Arrhythmia Atrial ﬁbrillation or ﬂutter, sick sinus syndrome, and ventricular arrhythmias 1
Cardiac Coronary artery disease, congestive heart failure, myocardial infarction, or ejection fraction  50% 1
Inﬂammatory bowel disease Crohn’s disease or ulcerative colitis 1
Diabetes Requiring treatment with insulin or oral hypoglycemics but not diet alone 1
Cerebrovascular disease Transient ischemic attack or cerebrovascular accident 1
Psychiatric disturbance Depression/anxiety requiring psychiatric consult or treatment 1
Hepatic, mild Chronic hepatitis, bilirubin > ULN 1.5  ULN, or AST/ALT > ULN 2.5  ULN 1
Obesity Patients with a body mass index > 35 kg/m2 1
Infection Requiring continuation of antimicrobial treatment after day 0 1
Rheumatologic SLE, RA, polymyositis, mixed CTD, polymyalgia rheumatica 2
Peptic ulcer Requiring treatment 2
Moderate/severe renal Serum creatinine > 2 mg/dL, on dialysis, or prior renal transplantation 2
Moderate pulmonary DLCO and/or FEV1 > 65%-80% or
Dyspnea on slight activity
2
Prior solid tumor Treated at any time point in the patient’s past history, excluding nonmelanoma skin cancer 3
Heart valve disease Except mitral valve prolapse 3
Severe pulmonary DLCO and/or FEV1  65% or
Dyspnea at rest or requiring oxygen
3
Moderate/severe hepatic Liver cirrhosis, bilirubin > 1.5  ULN, or AST/ALT > 2.5  ULN 3
ULN upper limit of normal; AST, Aspartate aminotransferase; ALT, Alanine aminotransferase; SLE, systemic lupus erythematosis; RA, rheumatoid arthritis; CTD,
connective tissue disease; DLco, Diffusion capacity of carbon monoxide; FEV1, Forced Expiratory volume at 1 second.
Supplementary Table 2
Variables Included in the Multivariate Analysis
 HCT-CI: 0 vs. >0
 Age: <50 vs. 50-59 vs. 60
 KPS: > 90 vs 90
 Gender: male vs. female
 Race: white vs. black vs. others
 Immunochemical subtype: IgG vs. IgA vs. light chain vs. others
 International stage: stage I vs. stage II vs. stage III
 Melphalan dose: 140 mg/m2 vs. 160 mg/m2 vs. 200 mg/m2
 Lines of chemotherapy: 1 vs. 2 vs. >2
 Chemotherapy: thalidomide/bortzomib/lenalidomide/thalidomide+
bortzomib/bortzomib+lenalidomide
 Sensitivity of chemotherapy before transplant: sensitive vs. resistant
 Time from diagnosis to transplant: 12 mo vs. >12 mo
Supplementary Table 3
Distribution of Comorbidities among the 3 Subgroups of Patients
HCT-CI ¼ 0
n (%)
HCT-CI ¼ 1-2
n (%)
HCT-CI > 2
n (%)
Comorbidity*
Moderate pulmonary 0 (0) 58 (16) 103 (34)
Diabetes 0 (0) 90 (25) 69 (23)
Psychiatric disturbance 0 (0) 58 (16) 83 (27)
Obesity 0 (0) 54 (15) 61 (20)
Cardiac 0 (0) 60 (17) 59 (20)
Moderate/severe renal 0 (0) 32 (9) 44 (15)
Arrhythmia 0 (0) 18 (5) 25 (8)
Cerebrovascular disease 0 (0) 10 (3) 11 (4)
Rheumatologic 0 (0) 10 (3) 12 (4)
Peptic ulcer 0 (0) 5 (1) 14 (5)
Infection 0 (0) 9 (2) 10 (3)
Inﬂammatory bowel disease 0 (0) 7 (2) 6 (2)
Mild hepatic 0 (0) 5 (2) 13 (4)
Severe pulmonary 0 (0) 0 (0) 100 (33)
Prior solid tumor (excluding
nonmelanoma skin cancer)
0 (0) 0 (0) 74 (25)
Heart valve disease 0 (0) 0 (0) 8 (3)
Moderate/severe hepatic 0 (0) 0 (0) 1 (<1)
Othery 123 (26) 129 (35) 118 (39)
No comorbidity 366 (74) 0 (0) 0 (0)
Values in parentheses are percents.
* HCT-CI scores of patients calculated from CIBMTR data forms.
y Other comorbidities include all diseases not included in HCT-CI score.
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